JP2016538292A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538292A5
JP2016538292A5 JP2016530991A JP2016530991A JP2016538292A5 JP 2016538292 A5 JP2016538292 A5 JP 2016538292A5 JP 2016530991 A JP2016530991 A JP 2016530991A JP 2016530991 A JP2016530991 A JP 2016530991A JP 2016538292 A5 JP2016538292 A5 JP 2016538292A5
Authority
JP
Japan
Prior art keywords
implant
biodegradable
bioerodible
plga
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538292A (ja
JP6675307B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065804 external-priority patent/WO2015073895A1/en
Publication of JP2016538292A publication Critical patent/JP2016538292A/ja
Publication of JP2016538292A5 publication Critical patent/JP2016538292A5/ja
Application granted granted Critical
Publication of JP6675307B2 publication Critical patent/JP6675307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016530991A 2013-11-15 2014-11-14 持続的薬物送達インプラントによる眼の状態の治療の方法 Active JP6675307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019225503A Division JP7022735B2 (ja) 2013-11-15 2019-12-13 持続的薬物送達インプラントによる眼の状態の治療の方法

Publications (3)

Publication Number Publication Date
JP2016538292A JP2016538292A (ja) 2016-12-08
JP2016538292A5 true JP2016538292A5 (https=) 2019-06-20
JP6675307B2 JP6675307B2 (ja) 2020-04-01

Family

ID=52001114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016530991A Active JP6675307B2 (ja) 2013-11-15 2014-11-14 持続的薬物送達インプラントによる眼の状態の治療の方法
JP2019225503A Active JP7022735B2 (ja) 2013-11-15 2019-12-13 持続的薬物送達インプラントによる眼の状態の治療の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019225503A Active JP7022735B2 (ja) 2013-11-15 2019-12-13 持続的薬物送達インプラントによる眼の状態の治療の方法

Country Status (24)

Country Link
US (2) US20150140062A1 (https=)
EP (2) EP3714875A1 (https=)
JP (2) JP6675307B2 (https=)
KR (3) KR20240058976A (https=)
CN (1) CN105764517A (https=)
AU (4) AU2014348369B2 (https=)
CA (1) CA2929689A1 (https=)
CL (1) CL2016001167A1 (https=)
CY (1) CY1123344T1 (https=)
DK (1) DK3068403T3 (https=)
ES (1) ES2819215T5 (https=)
HU (1) HUE050913T2 (https=)
IL (2) IL245548A0 (https=)
MX (2) MX2016006334A (https=)
MY (1) MY176039A (https=)
NZ (1) NZ719953A (https=)
PH (1) PH12016500869A1 (https=)
PL (1) PL3068403T3 (https=)
PT (1) PT3068403T (https=)
RU (1) RU2690841C1 (https=)
SG (1) SG10201809363SA (https=)
SI (1) SI3068403T1 (https=)
UA (1) UA122117C2 (https=)
WO (1) WO2015073895A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883070A (zh) * 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
AU2017321980B2 (en) 2016-09-02 2020-04-30 Alcon Inc. Implant applicators
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
JP2014508749A (ja) * 2011-02-11 2014-04-10 サイヴィーダ ユーエス,インコーポレイテッド 抗浮腫治療薬を使用する黄斑浮腫の治療方法

Similar Documents

Publication Publication Date Title
JP2016538292A5 (https=)
US20240082150A1 (en) Ocular compositions
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
WO2016042163A3 (en) Ophthalmic drug compositions
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
CY1117357T1 (el) Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων
RU2015134774A (ru) Имплантат для пролонгированной доставки лекарственного средства
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
RU2016119132A (ru) Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества
BR112015006929A2 (pt) sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HRP20220922T1 (hr) Usadive tablete naltreksona
MX2017001903A (es) Suministro de antioxidantes bioactivos, nanoencapsulados.
HRP20250123T1 (hr) Spojevi za liječenje bolesti vezanih s lipofuscinom
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
JP2024167340A (ja) コーティング眼用インプラント
Ashton pSivida and ophthalmic drug delivery
TH1601002766A (th) วิธีการบำบัดอาการเจ็บป่วยซึ่งเกี่ยวกับตาด้วยสิ่งปลูกฝังสำหรับนำส่งยาแบบทยอย
WO2016018454A3 (en) Compositions and methods employing bcl2 and bcl2 family members
de Borborema GarciaI et al. Tissue response evaluation of the mucosa of the tympanic cavity of guinea pigs, when receiving biodegradable implant1